Tolhuisen, Manon L.
Ernst, Marielle
Boers, Anne M. M.
Brown, Scott
Beenen, Ludo F. M.
Guillemin, Francis
Roos, Yvo B. W. E. M.
Saver, Jeffrey L.
van Oostenbrugge, Robert
Demchuck, Andrew M.
van Zwam, Wim
Jovin, Tudor G.
Berkhemer, Olvert A.
Muir, Keith W.
Bracard, Serge
Campbell, Bruce C. V.
van der Lugt, Aad
White, Phill
Hill, Michael D.
Dippel, Diederik W. J.
Mitchell, Peter J.
Goyal, Mayank
Caan, Matthan W. A.
Marquering, Henk A.
Majoie, Charles B. L. M.
,
Article History
Received: 9 June 2021
Accepted: 1 August 2021
First Online: 3 September 2021
Compliance with ethical standards
:
: The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Dr. Majoie reports grants from CVON/Dutch Heart Foundation, TWIN Foundation, European Commission, Dutch Health Evaluation program and Stryker outside the submitted work (paid to institution) and is shareholder of Nico.lab International Ltd. A.van der Lugt and D.W.J.Dippel are the recipients of unrestricted grants from Dutch Heart Foundation, Dutch Brain Foundation, The Netherlands Organisation for Health Research and Development, Health Holland Top Sector Life Science, Stryker, Medtronic, Penumbra Inc. and Cerenovus for the conduct of trials of acute treatment for stroke. Dr. Caan is shareholder of Nico.lab International Ltd. Dr. H.A. Marquering is co-founder and shareholder of Nico.lab International Ltd. Dr. Saver is an employee of the University of California. The University of California has patent rights in retrieval devices for stroke. The University of California Regents received payments on the basis of clinical trial contracts for the number of subjects enrolled in multicenter clinical trials sponsored by Medtronic, Stryker, Cerenovus and Rapid Medical; Dr. Saver served as an unpaid site investigator under these contracts. Dr. Saver has received contracted hourly payments and travel reimbursement for services as a scientific consultant advising on rigorous trial design and conduct to Medtronic, Stryker and Cerenovus. Dr. Saver has received contracted stock options for services as a scientific consultant advising on rigorous trial design and conduct to Rapid Medical. Prof White declares institutional unrestricted educational grants from Medtronic, Penumbra and Stryker, institutional grant from Microvention and personal consultancy work for Microvention. Prof K Muir has received fees for advisory boards or speaking from Boehringer Ingelheim, Biogen, Bayer, Daiichi Sankyo and ReNeuron, and receives institutional support from Boehringer Ingelheim for the ATTEST-2 trial.
: All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.